(FINalternatives) New York-based life sciences private equity company Aisling Capital has raised $280 million capital commitments for its latest fund to focus on bringing breakthrough medical treatments to market.
Ainsling Capital Raises $280M For Latest Life Sciences Fund
This entry was posted in Syndicated. Bookmark the permalink.